Marketcap : 176 mio$
Outlook:
Licensing - secure significant new deal
Evamist™ - VIVUS files Evamist marketing application with FDA
(achieved September 2006)
Testosterone MDTS® - VIVUS starts Phase 3 trials (H1 2007)
Contraceptive sprays - start proof of concept trials of combinations
Testosterone MD-Lotion® - complete Phase 2 trials (H1 2007)
New products - one successful proof of concept trial
Fentanyl UDTS™ - open IND with FDA for Phase 2
Cash - maintain above $10 million at all times
Add to My Watchlist
What is My Watchlist?
